Press Releases
2021
CHEMOMAB ANNOUNCES POSITIVE PHASE IB RESULTS OF ITS SPARK STUDY TESTING CM-101 IN NAFLD PATIENTS | January 5
2020
ANCHIANO THERAPEUTICS AND CHEMOMAB ANNOUNCE ENTRY INTO DEFINITIVE MERGER AGREEMENT | December 15
ANCHIANO ANNOUNCES STAN POLOVETS AS CHAIRMAN OF THE BOARD | May 26
ANCHIANO THERAPEUTICS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS | May 11
ANCHIANO APPOINTS STEVE DIPALMA AS CHIEF FINANCIAL OFFICER | May 5
ANCHIANO TO HOLD VIRTUAL MEETING OF SHAREHOLDERS | April 17
ANCHIANO THERAPEUTICS REPORTS YEAR-END 2019 FINANCIAL RESULTS | March 18
ANCHIANO THERAPEUTICS ANNOUNCES RECORD DATE FOR 2020 ANNUAL GENERAL MEETING OF SHAREHOLDERS | January 17
2019
ANCHIANO THERAPEUTICS REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE | November 15
ANCHIANO THERAPEUTICS CHAIRMAN STEPHEN HOFFMAN STEPS DOWN FROM BOARD | October 24
ANCHIANO THERAPEUTICS TO PRESENT AT THE LADENBURG THALMANN HEALTHCARE CONFERENCE| September 20
ANCHIANO THERAPEUTICS TO PRESENT AT THE BAIRD 2019 GLOBAL HEALTHCARE CONFERENCE | September 3
ANCHIANO THERAPEUTICS REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS | August 5
ANCHIANO THERAPEUTICS DELISTS ORDINARY SHARES FROM THE TEL AVIV STOCK EXCHANGE | June 19
ANCHIANO THERAPEUTICS ANNOUNCES APPOINTMENT OF SALAR ROSHAN AS HEAD OF BUSINESS DEVELOPMENT | May 29
ANCHIANO THERAPEUTICS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS | May 22
ANCHIANO THERAPEUTICS TO PRESENT AT THE OPPENHEIMER 29TH ANNUAL HEALTHCARE CONFERENCE | March 14
ANCHIANO THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS | March 12
ANCHIANO THERAPEUTICS ANNOUNCES CLOSING OF $30.5 MILLION INITIAL PUBLIC OFFERING | February 14
ANCHIANO THERAPEUTICS ANNOUNCES PRICING OF $30.5 MILLION INITIAL PUBLIC OFFERING | February 12
ANCHIANO THERAPEUTICS ANNOUNCES FILING OF F-1 REGISTRATION STATEMENT FOR U.S. INITIAL PUBLIC OFFERING | January 7
2018
ANCHIANO THERAPEUTICS ANNOUNCES APPOINTMENT OF DR. DAVID KERSTEIN AS NEW CHIEF MEDICAL OFFICER| November 26
ANCHIANO THERAPEUTICS REPORTS THIRD QUARTER 2018 FINANCIAL AND OPERATIONAL RESULTS | November 19
ANCHIANO THERAPEUTICS APPOINTS DR. STEPHEN HOFFMAN AND ROBERT CONNELLY TO ITS BOARD OF DIRECTORS | November 12
ANCHIANO THERAPEUTICS TO PRESENT AT H.C. WAINWRIGHT 20th ANNUAL GLOBAL INVESTMENT CONFERENCE| September 5
ANCHIANO THERAPEUTICS APPOINTS EFRAT MAKOV TO BOARD OF DIRECTORS| August 30
BIOCANCELL ANNOUNCES COMPANY NAME CHANGE TO ANCHIANO THERAPEUTICS | August 27
BIOCANCELL ANNOUNCES SECOND QUARTER FINANCIAL AND OPERATIONAL RESULTS | August 22
BIOCANCELL ANNOUNCES COMPLETION OF $23 MILLION PIPE FINANCING | July 3
NOTICE OF THE CONVENING OF AN EXTRAORDINARY GENERAL MEETING OF THE COMPANY’S SHAREHOLDERS | July 1
NOTICE OF THE CONVENING OF AN ANNUAL AND EXTRAORDINARY GENERAL MEETING OF THE COMPANY’S SHAREHOLDERS | April 26
BIOCANCELL ANNOUNCES $23 MILLION PIPE FINANCING| April 13
BIOCANCELL ANNOUNCES TWO NEW KEY HIRES IN CLINICAL DEVELOPMENT AND CLINICAL OPERATIONS | March 7
BIOCANCELL ANNOUNCES TERMS OF $25 MILLION FUNDRAISING ROUND | January 23
2017
SHAREHOLDERS TURN DOWN TENDER OFFER TO TAKE BIOCANCELL PRIVATE | December 28
INVESTORS INITIATE TENDER OFFER TO TAKE BIOCANCELL PRIVATE AHEAD OF PLANNED FUNDRAISING ROUND | December 11
BIOCANCELL ANNOUNCES UPDATED RESULTS FROM THE PHASE 2 CLINICAL TRIAL OF BC-819 AND BCG IN PATIENTS WITH BLADDER CANCER | November 15
BIOCANCELL ANNOUNCES EXPLORATION OF FUNDING ROUND CONDITIONED ON A GOING PRIVATE TRANSACTION | October 30
BIOCANCELL ANNOUNCES APPOINTMENT OF MS. RUTI ALON TO BOARD OF DIRECTORS | August 14
NOTICE OF THE CONVENING OF AN EXTRAORDINARY GENERAL MEETING OF THE COMPANY’S SHAREHOLDERS | August 1
2015
BIOCANCELL ADVANCES INTELLECTUAL PROPERTY PORTFOLIO IN THE U.S. | November 5
BIOCANCELL ADVANCES PHASE III CLINICAL PROGRAM FOR BLADDER CANCER | October 1
BIOCANCELL RECEIVES FDA FAST TRACK DESIGNATION FOR BC-819 FOR TREATMENT OF BLADDER CANCER PATIENTS | September 10
BIOCANCELL ANNOUNCES DEVELOPMENT OF NEW DIAGNOSTIC PRODUCT BC-830 | June 21
BIOCANCELL FILES INTERNATIONAL PATENT REQUEST FOR NEW DRUG FORMULATION | May 6
2014
BIOCANCELL RECEIVES OUTLINE FOR APPROVAL FOR TWO PHASE III BLADDER CANCER TRIALS | October 29
BIOCANCELL ANNOUNCES RESULTS OF BLADDER CANCER TRIAL | September 23
2013
BIOCANCELL ANNOUNCES FINAL PHASE IIB BLADDER CANCER TRIAL RESULTS | March 17
BIOCANCELL ANNOUNCES FIRST-STAGE PHASE IIB PANCREATIC CANCER TRIAL RESULTS | February 4
2012
BIOCANCELL ANNOUNCES PHASE I/IIA OVARIAN CANCER TRIAL RESULTS (update)| May 8
BIOCANCELL ANNOUNCES PHASE I/IIA OVARIAN CANCER TRIAL RESULTS | March 13
2011
BIOCANCELL RECEIVES FDA FAST TRACK DESIGNATION | October 4
BIOCANCELL TO COMMENCE PHASE IIB PANCREATIC CANCER CLINICAL TRIAL | July 21
2010
BIOCANCELL ANNOUNCES PHASE I/IIA PANCREATIC CANTER TRIAL RESULTS | December 27
BIOCANCELL RECEIVES ORPHAN DRUG APPROVAL FOR PANCREATIC CANCER TREATMENT | August 15
2009
BIOCANCELL COMMENCES PHASE I/IIA PANCREATIC CANCER TRIAL | November 29
BIOCANCELL USED BC-919 TO TREAT MICE WITH LUNG CANCER | August 13
BIOCANCELL COMPLETES $3.65 MILLION FUNDRAISING ROUND | August 3
2008
BIOCANCELL REVEALS PRE-CLINICAL RESULTS IN PANCREATIC CANCER TREATMENT | April 7
2007
BIOCANCELL ANNOUNCES PRE-CLINICAL DRUG EFFECTIVENESS IN OVARIAN CANCER AND LIVER METASTASES | October 23
BIOCANCELL ANNOUNCES SUCCESSFUL RESULTS IN CLINICAL TRIAL | September 24